GERMLINE COPY NUMBER POLYMORPHISM IDENTIFIED AS POTENTIAL PROGNOSTIC MARKER FOR PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER

被引：0
|
作者：
Yamamoto, Yoshiaki
Suehiro, Yutaka
Kawai, Yoshihisa
Inoue, Ryo
Matsumoto, Hiroaki
Matsuyama, Hideyasu
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.02.1340
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP44-09
引用
收藏
页码：E567 / E567
页数：1
相关论文
共 50 条
  • [1] Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression
    Yamamoto, Yoshiaki
    Suehiro, Yutaka
    Suzuki, Atomu
    Nawata, Ryosuke
    Kawai, Yoshihisa
    Inoue, Ryo
    Hirata, Hiroshi
    Matsumoto, Hiroaki
    Yamasaki, Takahiro
    Sasaki, Kohsuke
    Matsuyama, Hideyasu
    ONCOLOGY LETTERS, 2017, 14 (01) : 1193 - 1199
  • [2] Germline DNA copy number polymorphism to predict the efficacy of BCG therapy for non-muscle invasive bladder cancer
    Yamamoto, Yoshiaki
    Ozawa, Sho
    Samoto, Masahiro
    Mori, Junichi
    Inoue, Ryo
    Yano, Seiji
    Hirata, Hiroshi
    Matsumoto, Hiroaki
    Matsuyama, Hideyasu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] FAM81A GERMLINE COPY NUMBER POLYMORPHISM MAY PREDICT THE EFFICACY OF BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
    Yamamoto, Yoshiaki
    Samoto, Masahiro
    Mori, Junichi
    Shimizu, Kosuke
    Inoue, Ryo
    Yano, Seiji
    Matsumoto, Hiroaki
    Matsuyama, Hideyasu
    JOURNAL OF UROLOGY, 2019, 201 (04): : E900 - E901
  • [4] Evaluating cell cycle progression score as a prognostic marker for non-muscle invasive bladder cancer (NMIBC)
    Weight, Christopher J.
    Murugan, Paari J.
    Chesla, David
    Tejpaul, Resha
    Soubra, Ayman
    Boshoven, William
    Sangale, Zaina
    Rajamani, Saradha
    Stone, Steven
    Lane, Brian R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Copy Number Aberrations Predict Patient Prognosis in Non-Muscle Invasive Bladder Cancer
    Matsuyama, H.
    Eguchi, S.
    Sasaki, K.
    UROLOGY, 2012, 80 (03) : S62 - S63
  • [6] Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNEI in non-muscle invasive bladder cancer
    Chu, In-Sun
    Leem, Sun-Hee
    CANCER RESEARCH, 2016, 76
  • [7] Molecular predictors of non-muscle invasive bladder cancer progression
    Smal, M.
    Rolevich, A.
    Nikitchenko, N.
    Krasny, S.
    Goncharova, R.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 541 - 541
  • [8] Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer
    van Kessel, Kim E. M.
    van der Keur, Kirstin A.
    Dyrskjot, Lars
    Algaba, Ferran
    Welvaart, Naeromy
    Beukers, Willemien
    Segersten, Ulrika
    Keck, Bastian
    Maurer, Tobias
    Simic, Tatjana
    Horstmann, Marcus
    Boormans, Joost L.
    Real, Francisco X.
    Malats, Nuria
    Malmstronn, Per-Uno
    Orntoft, Torben F.
    Zwarthoff, Ellen C.
    CANCER RESEARCH, 2016, 76
  • [9] AGR2 is a marker of disease progression and a potential therapeutic target in non-muscle invasive bladder cancer.
    Maia, Andreia
    Martin-Fernandez, Javier
    Gaya Sopena, Josep Maria
    Rodriguez-Faba, Oscar
    Palou Redorta, Joan
    Castillo-Martin, Mireia
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 55 - 55
  • [10] Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer
    Bic-Na Song
    Seon-Kyu Kim
    In-Sun Chu
    Experimental & Molecular Medicine, 2017, 49 : e282 - e282
12345